Recorded December 7, 2023. This transcript has been edited for clarity.
Robert A. Harrington, MD: Hi. This is Bob Harrington from Weill Cornell Medicine on theheart.org | Medscape Cardiology. Today we are taping my favorite podcast of the year, the wrap-up that I've done for a number of years now with my good friend and colleague, Mike Gibson. We get to talk about some of the hot news in cardiology that played out over the course of the year. We tend to go through the trials and then maybe hit some big topics on either the news of cardiology or the policy issues affecting cardiology. And along the way, Mike and I might add a few other topics.
Typically what we've done is to group topics like heart failureintervention, and lipids. This year we're going to walk through the calendar year, and we'll start with ACC '23, work our way to ESC '23, and end up at AHA '23. So with that as the plan, I'm really pleased to be joined by Mike Gibson. Mike is an interventional cardiologist at the Beth Israel Deaconess Lahey Hospital in Boston. He's a professor of medicine at Harvard Medical School, and he is the CEO of the BAIM Institute for Clinical Research, an academic research organization.
